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Abstract Machado–Joseph disease (MJD) is a late-onset
autosomal dominant neurodegenerative disorder, which is
caused by a coding (CAG)n expansion in the ATXN3 gene
(14q32.1). The number of CAG repeats in the expanded
alleles accounts only for 50 to 75 % of onset variance, the
remaining variation being dependent on other factors. Differ-
ential allelic expression of ATXN3 could contribute to the
explanation of different ages at onset in patients displaying
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similar CAG repeat sizes. Variation in 5′ regulatory regions of
the ATXN3 gene may have the potential to influence expression
levels and, ultimately, modulate the MJD phenotype. The main
goal of this work was to analyze the extent of sequence varia-
tion upstream of the ATXN3 start codon. A fragment containing
the core promoter and the 5′ untranslated region (UTR) was
sequenced and analyzed in 186 patients and 59 controls (490
chromosomes). In the core promoter, no polymorphisms were
observed. In the 5′UTR, only one SNP (rs3814834) was found,
but no improvements on the explanation of onset variance were
observed, when adding its allelic state in a linear model. Ac-
cordingly, in silico analysis predicted that this SNP lays in a
nonconserved position for CMYB binding. Therefore, no func-
tional effect could be predicted for this variant.
Keywords Ataxin-3 . 5′ regulatory regions . 5′UTR .MJD .
Promoter . SCA3
Introduction
Machado–Joseph disease (MJD) or spinocerebellar ataxia
type 3 (OMIM #109150) is an autosomal dominant neurode-
generative disorder. Most patients show the first symptoms in
adulthood (mean ~40 years), but onset extremes of 4 and
70 years have been described [1, 2]. The MJD phenotype is
complex and pleomorphic, involving the cerebellar, ocular
motor, pyramidal, extrapyramidal, and peripheral motor sys-
tems, at variable degrees [2].
MJD’s causative mutation corresponds to an expansion of a
(CAG)n motif in exon 10 of the ATXN3 gene (14q32.1) [3, 4].
Normal alleles range from 12 to 44 CAG repeats, while
expanded alleles present more than 52 repeats [5, 6]. The size
of the expanded tract is incompletely correlated with the age at
onset, explaining from 50 to 75 % of its variance [7, 8]. Other
factors (genetic, environmental, or both) should contribute to
the clinical variability observed; to date, only the APOE gene
has been established as a modifier of the age at onset in MJD
[9], while GRIK2, IL1B, and NEDD8 genes have been sug-
gested as possible modifiers [10].
The ATXN3 gene encodes for ataxin-3, which displays
distinct isoforms [11], and presents, in its mutated form, an
abnormal elongation of the polyglutamine tract near its C-
terminus [3]. This gene is ubiquitously expressed, in neuronal
and non-neuronal tissues, thus the presence of the mutated
gene cannot explain by itself the selective neuronal degenera-
tion observed inMJD (reviewed in [6]). The idea that the levels
of expression of the mutant allele may contribute to neuro-
degeneration has been supported by observations from model-
based studies [12, 13], as well as by the earlier onset and faster
progression of the disease seen in homozygous patients [1, 14,
15]. Therefore, we can hypothesize that higher expression
levels of mutant ataxin-3 in heterozygous patients may also
be associated with a more severe phenotype, namely with a
decrease in age at onset.
Variation in noncoding regulatory regions, i.e., those at 5′,
may affect gene expression levels in an allele-specific manner
[16]. Besides the promoter, gene expression levels may be
further influenced by cis-regulatory elements located in the 5′
untranslated region (UTR) [17]. The ATXN3 promoter has
been described as being directly upstream of the gene. Its core
region of transcriptional activation, containing consensus
sequences for a CCAAT box and SP1 binding sites, appears
to be located between −291 and the transcription start site
[18]. Although the genomic structure of the ATXN3 5′ flank-
ing region has already been described, the extent of variation
in this region, which could be involved in transcriptional and
translational regulation, remains unexplored.
The main goal of this work was to describe the variation
upstream of the ATXN3 gene start codon, in its core promoter
and 5′ UTR, in MJD patients and in controls. Furthermore,
this work aimed to investigate potential modulating effects of
such putative variation on the age at onset of MJD.
Patients and Methods
Subjects
After informed consent, blood samples were collected from
186 MJD patients (59 from the Azores, 67 from mainland
Portugal, and 60 from Brazil) and 59 apparently healthy Cau-
casian controls (molecularly excluded for the CAG expan-
sion). DNA was extracted from whole blood using standard
procedures. The age at onset was available for the series of
MJD patients in the study, and it was defined as the age at
which the first complaints of gait instability or diplopia were
noticed (more details in [9]). The (CAG)n tract size in ATXN3
gene was also available, and had been determined according to
Bettencourt et al. [19].
Amplification and Sequencing
A fragment of 816 bp, containing the core promoter and the
5′ UTR (Fig. 1), as well as downstream sequences of the
ATXN3 gene, was amplified using the following set of
primers: P-1aF (5′-CAAGTGCTGGGTTTTGGGAG-3′)
and P-1R (5′-AAAGCGATGGAAAGTGACGG-3′). An ini-
tial denaturation step (95 °C, 5 min) was followed by 37
cycles of denaturation (94 °C, 30 s), annealing (56 °C, 30 s),
and extension (72 °C, 45 s), and a last step of extension (72 °C,
7 min). PCR products were purified using a Spin Kit
(Genomed). All samples were sequenced in both forward and
reverse directions, using primers P-1aF and P-1aR (5′-
ACGCGGACACTCACTTTCTC-3′), and whenever necessary
using P-1R. Sequence reactions were carried out using the
Cerebellum
Author's personal copy
BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems) and run in an ABI 310 sequencer. All sequence
alignments, namely of the obtained sequences with the Homo
sapiens genomic DNA sequence (GenBank AB038653.1),
were performed with BioEdit v7.0.9.0 [20].
In Silico Sequence Analysis
Two predicting tools, TFBIND (http://tfbind.ims.u-tokyo.ac.
jp) [21], and MATCH™ (http://www.gene-regulation.com/
pub/programs.html#match) [22], were used to find differ-
ences in putative transcription factor (TF) binding sites due
to rs3814834.
Statistical Analysis
Genotypic and allelic frequencies of rs3814834 were deter-
mined. Conformity with the Hardy–Weinberg equilibrium
expectations was tested. An exact test of differentiation evalu-
ated differences in genotypic frequencies for this SNP between
patients and controls. Analyses were performed using the Arle-
quin software v.3.1 [23], with a level of significance of 0.05.
OpenEpi v.2 proportion calculator (www.openepi.com) was
used to determine the 95 % confidence intervals for the allele
frequencies present in the Reference SNP Cluster Report of
rs3814834 (available at http://www.ncbi.nlm.nih.gov), for the
European population (EGP_CEPH-PANEL).
Linear regression analyses were used to test the effect of
several variables on age at onset of MJD patients. The
multivariate linear model included the following covariates:
CAG number in expanded and in normal alleles, genotypes
for rs3814834, geographical origin, and gender of the pa-
tient. Age at onset, stratified by rs3814834 genotypes, was
adjusted for the mean number of CAGs in the expanded
ATXN3 allele, after fitting a linear regression model. Regres-
sion analyses were performed using SPSS v.15.0 [24].
Fig. 1 Diagram representing the genomic region containing the
ATXN3 gene (grey boxes representing the coding exons, and white
boxes the UTRs), with illustration of the analyzed 5′ regulatory
regions, including a portion of the promoter (with the core promoter
underlined in blue, from −59 to −291) and the 5′ UTR (with the
rs3814834 at −31, and the binding site for CMYB underlined in red).
Indications of the start codon (+1 start), and the (CAG)n tract location
are also given
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Results
Sequence analysis of 420 bp of the ATXN3 gene promoter
failed to reveal any polymorphism in this region (N0490
chromosomes). At the 5′ UTR, a previously described poly-
morphism, c.−31C>T (rs3814834), was observed (Fig. 1), in
both patients and controls. Genotypic frequencies (Table 1)
were in conformity with Hardy–Weinberg expectations. In
control samples, all three possible genotypes (C/C, C/T, and
T/T) were observed (Table 1). However, in MJD samples, the
T/T genotype was absent (Table 1), resulting in statistically
significant differences in genotypic frequencies between
patients and controls (p00.00355). Nevertheless, allelic fre-
quencies of 97.7 % (CI95 %092.7–99.6) for the C variant, and
of 2.3 % (CI95 %00.4–7.3) for the T variant, are reported for
the European population (EGP_CEPH-PANEL), being simi-
lar to those obtained for the MJD patients.
For the studied series of patients, a summary of descrip-
tive statistics is shown in Table 2. Although patients with the
C/T genotype (rs3814834) presented an earlier mean age at
onset than those with the C/C genotype, such difference
disappeared after adjusting the age at onset for the (CAG)n
size (Table 2). The expected negative correlation between
the size of the (CAG)n tract in the expanded alleles and the age
at onset was confirmed in this MJD series (r0−0.773, p<
0.001), explaining by itself 59.5 % of onset variance. In
relation to the linear model accounting only for the CAG
repeat size in expanded alleles, the multivariate model im-
proved the predictability of the age at onset in about 5.4 %
(accounting now for 64.9 % of onset variance). This model
counted with significant contributions from the geographical
origin (p<0.001) and gender of the patients (p00.005), with
male patients presenting earlier ages at onset. Both the
(CAG)n tract size in the normal alleles as well as the allelic
state of rs3814834 showed no significant effects.
In silico analysis showed that the rs3814834 falls within
the recognition site for the binding of CMYB. However, it
lies in a nonconserved position for CMYB binding, not
altering the binding of this TF.
Discussion
The absence of polymorphisms in the 490 analyzed chro-
mosomes supports the idea of a conserved ATXN3 promoter.
This is in agreement with what was previously obtained by
Costa et al. [25], who analyzed the atxn3 promoter in mice
and found it to be highly conserved even between species.
In the 5′ UTR, the variation found does not seem to alter the
putative binding of CMYB, thus no functional effect can be
predicted for this variant. Results from in silico analysis are
in agreement with the absence of improvement of the linear
model when adding the allelic state for the detected SNP
(rs3814834). The use of age at onset as the only available
measure of phenotype severity constitutes a limitation of our
study, given its approximate nature, and especially because
variants in regulatory regions may be associated with the
disease course (in terms of progression rate and severity, for
example), but not with the disease onset.
Supporting our rationale about the effect of variants in 5′
regulatory regions, several studies have reported that var-
iants in these regions of certain genes can be associated with
the onset of neurodegenerative diseases, as is the case of
Alzheimer’s disease (e.g., [26]) or Parkinson’s disease (e.g.,
Table 1 Genotype and allele frequencies for the c.−31C>T polymor-
phism (rs3814834) in MJD patients and controls
Frequency (%) MJD patients (N0186) Controls (N059)
Genotypes
C/C 91.9 78.0
C/T 8.1 18.6
T/T 0.0 3.4
Alleles
C 96.0 87.3
T 4.0 12.7
Table 2 Descriptive statistics for the MJD patients studied
Characteristics rs3814834 Total
C/C C/T
Number of patients (%) 171 (91.9) 15 (8.1) 186
Population
Portugal
Azores 54 (91.5) 5 (8.5) 59
Mainland 62 (92.5) 5 (7.5) 67
Brazil 55 (91.7) 5 (8.3) 60
Gender
Male 84 (90.3) 9 (9.7) 93
Female 87 (93.5) 6 (6.5) 93
Age at onset
Mean±SE (years) 36.97±0.94 34.07±2.94 38.58±0.90
Adjusted
onseta±SE (years)
38.66±0.61 38.54±1.56
Range (years) 12–70 12–57 12–70
CAG repeat length
Normal
Mean±SE 21.71±0.38 25.07±0.74 21.98±0.36
Range 14–37 19–28 14–37
Expanded
Mean±SE 72.73±0.29 74.27±0.83 72.85±0.27
Range 63–82 68–81 63–82
a Adjusted for the mean size of expanded CAG repeats in the patient
sample
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[27]). Similarly to our results, polymorphisms in the 5′ regu-
latory regions of the HTT gene have not been significantly
associated with the age at onset of Huntington’s disease (HD)
[28]. Nevertheless, contributions of other variants, further
upstream of the analyzed regions or even in other regulatory
regions (e.g., 3′ UTR), to differential allelic expression of the
ATXN3 gene, have not been a matter of study.
Although it was out of the scope of this paper, results from
the regression analysis suggested that geographical origin
(reflecting environmental and/or other population specific fac-
tors) as well as gender of the patients (suggesting the existence
of sex-linked factors) may bemodulating the toxic effect of the
polyglutamine expansion in this series of patients. Several
examples of environmental and/or sex-linked factors have
been reported for other polyglutamine diseases, such as HD
(e.g., [29–31]). Specific analyses concerning the effect of such
factors in MJD warrant further investigation in future studies.
Summary
In this first report on the extent of genetic variation upstream of
the ATXN3 start codon in MJD patients and controls, the core
promoter region was shown to be highly conserved. Although
the present series of patients previously enabled the detection of
a modifier effect of APOE ε2, it was not possible to demonstrate
an impact on disease onset related to the SNP (rs3814834) found
in the 5′ UTR.
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